Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HPRT1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HPRT1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW. |
View HPRT1 Products |
| Gene Delivery | HPRT1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. High-titer transduction ready. |
View HPRT1 Products |
| Benchmark Ab | Anti-HPRT1 Recombinant Antibody High-affinity positive control for expression profiling and assay validation. |
View HPRT1 Products |
| Validator | HPRT1 siRNA Set For target-specific knockdown and phenotypic verification. |
View HPRT1 Products |
| Related Target A | IMPDH2 Key rate-limiting enzyme in de novo guanine nucleotide synthesis, essential for metabolic synergy studies. |
View IMPDH2 Products |
| Related Target B | APRT Parallel purine salvage pathway enzyme, critical for studying compensatory resistance mechanisms. |
View APRT Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic activity assessment | High-purity (>95%) recombinant proteins with verified sequence integrity and low endotoxin levels. |
| Off-target screening (Parasite vs. Human) | Human recombinant HPRT1 available as a negative selection counter-screen for antimalarial drug discovery. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included for assay standardization. |
| False Positives | Validated siRNA pool included for target knockdown and specificity checks. |
Live HPRT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HPRT1 therapeutics is intensifying, with major players shifting focus from traditional housekeeping controls to metabolic target modulation. HPRT1 (Hypoxanthine Phosphoribosyltransferase 1) is a central enzyme in the purine salvage pathway. While historically utilized as a reliable qPCR reference gene, emerging oncology and parasitology pipelines have repositioned HPRT1 as a therapeutic vulnerability. In oncology, rapidly proliferating cancer cells overexpress HPRT1 to meet high nucleotide demands, and its activity directly modulates sensitivity to thiopurine prodrugs (e.g., 6-thioguanine). Simultaneously, selective inhibition of parasitic HPRT counterparts over human HPRT1 remains a cornerstone of antimalarial drug design. As first-generation therapies reach the clinic, the next wave of R&D is targeting selective small-molecule inhibitors and combination regimens to overcome nucleotide salvage-mediated drug resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Oncology (Leukemia, Solid Tumors), Malaria | Enzymatic Inhibition Assay (Need high-purity recombinant HPRT1) |
| Thiopurine Co-therapies | Global Pharma, Clinical Consortia | Inflammatory Bowel Disease, ALL | Genotypic Resistance Screening (Need mutant proteins and siRNA validators) |
| Gene Therapy / Correction | Gene Therapy Developers | Lesch-Nyhan Syndrome | Functional Rescue Assay (Need high-titer Lentivirus for stable cell lines) |